<DOC>
	<DOC>NCT00002147</DOC>
	<brief_summary>To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.</brief_summary>
	<brief_title>Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.</brief_title>
	<detailed_description>Patients receive DOX-SL every 3 weeks for up to 20 cycles.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma, Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Patients must have: AIDSrelated Kaposi's sarcoma that requires systemic chemotherapy. EITHER a medical indication for continuation of DOXSL following treatment on another DOXSL protocol, OR no remaining treatment options other than DOXSL. Prior Medication: Allowed: Prior anthracyclines. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Cardiac ejection fraction &lt; 50 percent or clinically significant cardiac disease. Eligibility for a Liposomal Technology comparative protocol. Concurrent Medication: Excluded: Other cytotoxic chemotherapy. Patients with the following prior condition are excluded: History of idiosyncratic or allergic reaction to anthracyclines. Prior Medication: Excluded: Chemotherapy within the past 3 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Sarcoma, Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>